He also expects sales to rise at an 18% compounded annual growth rate through 2015.

FORBES: Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer Treatments

The company noted the raised earnings guidance reflected increased sales expectations and shares repurchased through June 30, interest on borrowings, and a lower full year tax rate.

FORBES: It's A Beautiful Day For Tempur-Pedic